Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | ATF1 | P18846 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.30 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26288026 | 0.80 | GLP1R (0.33) | GLP1RMEN1KMT2AAURKA | |
| SCHEMBL1424004 | 0.79 | TDP1 (0.36) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1935288 | 0.79 | GLP1R (0.41) | GLP1RKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3197662 | 0.78 | MEN1 (0.39) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11432532 | 0.78 | GLP1R (0.33) | GLP1RKDM4EMEN1KMT2AAURKA | |
| SCHEMBL3068435 | 0.78 | CSNK1A1 (0.37) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15434051 | 0.77 | TDP1 (0.44) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1935256 | 0.77 | JAK1 (0.33) | MEN1KMT2A | |
| SCHEMBL1938038 | 0.77 | GBA1 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1443354 | 0.75 | KDM4E (0.50) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3813819-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3075730-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2785699-B1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20130096102-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | GLP1R 4196/4885KDM4E 1178/4885SMN1; SMN2 1342/4885 |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | GLP1R 4546/4885KDM4E 1278/4885SMN1; SMN2 2817/4885 |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | GLP1R 4546/4885KDM4E 1278/4885SMN1; SMN2 2817/4885 |
| US-20130096102-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | GLP1R 89/4885KDM4E 2542/4885SMN1; SMN2 212/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | GLP1R 93/4885KDM4E 1190/4885SMN1; SMN2 1477/4885 |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | GLP1R 65/4885KDM4E 2684/4885SMN1; SMN2 211/4885 |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | GLP1R 4546/4885KDM4E 1278/4885SMN1; SMN2 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.